Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss

Objectives: Dual incretin agonists are among the most effective pharmaceutical treatments for obesity and type 2 diabetes to date. Such therapeutics can target two receptors, such as the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor in t...

Full description

Bibliographic Details

Published in:	Molecular Metabolism
Main Authors:	Jordan Wean, Allison Ho Kowalsky, Rhianna Laker, Sarah Will, Daniel J. Drucker, Christopher J. Rhodes, Randy J. Seeley
Format:	Article
Language:	English
Published:	Elsevier 2025-05-01
Subjects:	Incretin GLP-1 GIP Obesity Anti-obesity medication Dual-incretin agonism
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212877824002059